Drug Trial News

RSS

JAK inhibitors or type I interferon shown to reduce mortality in COVID-19

Now, a new study by researchers at Yale University and published on the preprint server medRxiv in August 2020 reports that the use of two drug categories, namely, JAK inhibitors and Type I interferons (IFNs), is associated with a dramatic improvement in mortality in COVID-19.

13 Aug 2020

Combination regimen improves overall survival in certain patients with AML

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

12 Aug 2020

Researchers recommend inclusion of pregnant and breastfeeding women in COVID-19 vaccine trials

Researchers from the United Kingdom have published their views on the inclusion of pregnant women in clinical trials for vaccines against the novel coronavirus and the related challenges this presents. Their article titled, “Inclusion of pregnant women in COVID-19 vaccine development”, was published yesterday in The Lancet Infectious Diseases.

12 Aug 2020

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.

11 Aug 2020

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

A group of Chinese researchers recently conducted a phase 2 clinical trial to further evaluate the immunogenicity and safety of SARS-CoV-2 inactivated vaccine known as CoronaVac. The results are currently available on the medRxiv preprint server and demonstrate that the vaccine is well tolerated and without any notable dose-related safety concerns, which opens the door for phase 3 clinical trial.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

First clinical trial could become an effective way to deliver chemotherapy to abdominal cancer patients

City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options.

11 Aug 2020

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19.

11 Aug 2020

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health, Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

10 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

New document includes practical resources to improve diversity and inclusion in clinical research

The COVID-19 pandemic has illuminated social and health inequities and the impact of structural and systemic racism in society.

7 Aug 2020

Vitamin D does not reduce risk of depression or mood changes

Several studies have shown that those with Vitamin D deficiency also have symptoms of depressive illness. The authors wrote, "Low levels of 25-hydroxyvitamin D have been associated with a higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials."

5 Aug 2020

Panthera’s oncology clinical trial sites in the UK are open for research activities

Previous
1
...
77
78
79
80
81
82
83
...
1149
Next

Drug Trial News

JAK inhibitors or type I interferon shown to reduce mortality in COVID-19

Combination regimen improves overall survival in certain patients with AML

Researchers recommend inclusion of pregnant and breastfeeding women in COVID-19 vaccine trials

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

First clinical trial could become an effective way to deliver chemotherapy to abdominal cancer patients

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

New document includes practical resources to improve diversity and inclusion in clinical research

Vitamin D does not reduce risk of depression or mood changes

Panthera’s oncology clinical trial sites in the UK are open for research activities

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News